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1. INTRODUCTION {#cam42623-sec-0005}
===============

Core needle biopsy (CNB) has become a standard method for breast cancer diagnosis, due to the avoidance of more invasive biopsies. However, the natural limitation in the volume of sampling of this biopsy method can result in underestimation. For example, patients diagnosed with ductal carcinoma in situ (DCIS) by CNB can be upstaged to DCIS with microinvasion (DCISM) or invasive breast cancer (IBC).[1](#cam42623-bib-0001){ref-type="ref"}, [2](#cam42623-bib-0002){ref-type="ref"} According to previous studies, approximately 26% of patients diagnosed with DCIS were upstaged to invasive disease on the final pathological diagnosis, with an overall range 8.8%‐51.5%.[3](#cam42623-bib-0003){ref-type="ref"}, [4](#cam42623-bib-0004){ref-type="ref"}, [5](#cam42623-bib-0005){ref-type="ref"}, [6](#cam42623-bib-0006){ref-type="ref"}, [7](#cam42623-bib-0007){ref-type="ref"}, [8](#cam42623-bib-0008){ref-type="ref"}, [9](#cam42623-bib-0009){ref-type="ref"}, [10](#cam42623-bib-0010){ref-type="ref"}, [11](#cam42623-bib-0011){ref-type="ref"}

With the presence of upstaging in patients preoperatively diagnosed with DCIS by CNB, a major concern for surgeons is whether to evaluate the ALNs at the primary operation. Both National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines recommended that sentinel lymph node biopsy (SLNB) should be performed in patients for whom axillary evaluation is difficult in stage two operation, such as patients who received mastectomy.[12](#cam42623-bib-0012){ref-type="ref"}, [13](#cam42623-bib-0013){ref-type="ref"} Also, patients highly suspicious for IBC either with palpable mass or high‐risk images in mammography should receive axillary evaluation in case of upstaging in ALNs status.[9](#cam42623-bib-0009){ref-type="ref"}, [12](#cam42623-bib-0012){ref-type="ref"}, [13](#cam42623-bib-0013){ref-type="ref"}, [14](#cam42623-bib-0014){ref-type="ref"}

In this study, we identified clinicopathological factors associated with upstaging and ALNs metastasis in patients preoperatively diagnosed with DCIS by CNB. The aim of this study was to identify whether axillary evaluation can be omitted in these patients.

2. METHODS {#cam42623-sec-0006}
==========

2.1. Patients {#cam42623-sec-0007}
-------------

We retrospectively reviewed the medical records of cN0 patients preoperatively diagnosed with pure DCIS by CNB who underwent axillary evaluation between August 2006 and December 2015 at Fudan University Shanghai Cancer Center (FUSCC). Patients were excluded if: (a) patients were male; (b) neoadjuvant chemotherapy was received prior to surgery; (c) patients had bilateral breast cancer; or (d) patients had a history of breast cancer. The study was approved by the Ethics Committee of FUSCC.

2.2. Surgical procedures and axillary evaluation {#cam42623-sec-0008}
------------------------------------------------

All patients underwent histological diagnosis preoperatively via a 14‐gauge core needle biopsy. Patients who were inclusive underwent the primary operation in our institution, including mastectomy and breast‐conserving surgery (BCS). The final pathological findings were classified as pure DCIS, DCISM, and IBC. Microinvasion was defined as invasive portion no more than 1mm. Immunostaining for estrogen receptor (ER) and progesteron receptor (PR) was performed and cases with 1% or more positive staining were considered as positive staining. Human epidermal growth factor receptor 2 (HER2) positivity was defined as those cases where immunohistochemistry (IHC) staining was 3+ alone or 2+ with fluorescence in situ hybridization (FISH) positivity.

In this study, SLNB was performed at the same time as the breast surgery. Histological assessment with hematoxylin‐eosin staining performed postoperatively served as the golden standard. A positive SLN was defined as the presence of either micrometastasis (\>200 cells or \>0.2 mm, but \<2.0 mm) or macrometastasis (\>2.0 mm) identified on hematoxylin‐eosin staining. Patients with intraoperatively positive SLNs were required to undergo axillary lymph nodes dissection (ALND). Level I and level II ALND was performed according to a standard ALND procedure.

2.3. Statistical analysis {#cam42623-sec-0009}
-------------------------

The clinicopathological variables were compared between pure DCIS group and upstaging group according to the final pathological findings using Chi‐square test for categorical variables. Also, variables were compared between the axillary metastasis group and the axillary nonmetastasis group. Multivariate logistic regression analyses were performed to investigate the risk predictors of upstaging and axillary metastasis. Two‐tailed *P* values were adopted, and *P* \< .05 was considered significant. All statistical analyses were performed using SPSS statistical software version 17.0 (IBM).

3. RESULTS {#cam42623-sec-0010}
==========

3.1. Baseline characteristics {#cam42623-sec-0011}
-----------------------------

A total of 604 patients met the criteria. The average age of these patients was 51.00 years (range 24‐83 years). Clinicopathological characteristics of the entire cohort are shown in Table [1](#cam42623-tbl-0001){ref-type="table"}. At the initial presentation of breast cancer, 526 (87.09%) patients presented with lumps, with an average diameter of 24.68 mm (range 10‐79 mm). The majority (548, 90.73%) underwent mastectomy, and 56 (9.27%) patients chose BCS. Overall, 121 (20.03%) and 193 (31.95%) patients were upstaged to DCISM and IBC on final pathology, respectively. Several patients with combined pathological type were detected, divided by final pathology (Table [2](#cam42623-tbl-0002){ref-type="table"}). After examining axillary status in these patients, we found that patients combined with invasive micropapillary carcinoma in IBC group were more likely to have positive ALNs (66.67% vs 15.51%, *P* \< .001).

###### 

Baseline clinicopathological characteristics of patients preoperatively diagnosed with DCIS by CNB

  Variables                       Total N = 604   \%
  ------------------------------- --------------- -------
  Age                                              
  ≤50                             309             51.16
  \>50                            295             48.84
  Menopause                                        
  No                              297             49.17
  Yes                             282             46.69
  Unknown                         25              4.14
  BC family history                                
  No                              481             79.64
  Yes                             123             20.36
  BMI                                              
  \<25                            457             75.66
  ≥25                             126             20.86
  Unknown                         21              3.48
  Tumor size on ultrasonography                    
  cT1                             229             37.91
  cT2‐3                           331             54.80
  Unknown                         44              7.28
  Calcification on mammography                     
  Yes                             363             60.10
  No                              79              13.08
  Unknown                         162             26.82
  MRI                                              
  No                              248             41.06
  Yes                             356             58.94
  Quadrate                                         
  Upper outer                     220             36.42
  Others                          384             63.58
  Surgical methods                                 
  Mastectomy                      548             90.73
  BCS                             56              9.27
  Axillary evaluation                              
  SLNB                            513             84.93
  ALND                            91              15.07
  Histological grade                               
  Non‐high                        299             49.50
  High                            253             41.89
  Unknown                         52              8.61
  Tumor size on pathology                          
  ≤2 cm                           208             34.44
  \>2 cm                          396             65.56
  Number of lesions                                
  Unifocal                        581             96.19
  Multifocal                      23              3.81
  Ki67                                             
  ≤14%                            136             22.51
  \>14%                           418             69.20
  Unknown                         50              8.29
  Molecular type                                   
  ER+HER2−                        227             37.58
  ER+HER+                         113             18.71
  ER−HER2+                        200             33.11
  ER−HER2−                        54              8.94
  Unknown                         10              1.66

Abbreviations: ALND, axillary lymph node dissection; BC, breast cancer; BCS, breast‐conserving surgery; BMI, body mass index; CNB, core needle biopsy; DCIS, ductal carcinoma in situ; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; MRI, magnetic resonance imaging; SLNB, sentinel lymph node biopsy.

John Wiley & Sons, Ltd

###### 

Final pathology in patients with combined pathological type

+----------------------------------------------------------------+----------------+-----------------+---------------+
| Specific combined pathological type                            | DCIS (N = 290) | DCISM (N = 121) | IBC (N = 193) |
|                                                                |                |                 |               |
|                                                                | n (%)          | n (%)           | n (%)         |
+================================================================+================+=================+===============+
| Other carcinoma in situ[a](#cam42623-note-0005){ref-type="fn"} | 20 (6.90)      | 3 (2.48)        | 3 (1.55)      |
+----------------------------------------------------------------+----------------+-----------------+---------------+
| Other invasive type[b](#cam42623-note-0006){ref-type="fn"}     | 0 (0)          | 0 (0)           | 14 (7.25)     |
+----------------------------------------------------------------+----------------+-----------------+---------------+
| Sclerosing adenosis                                            | 13 (4.48)      | 4 (3.31)        | 0 (0)         |
+----------------------------------------------------------------+----------------+-----------------+---------------+
| Necrosis                                                       | 7 (2.41)       | 3 (2.48)        | 0 (0)         |
+----------------------------------------------------------------+----------------+-----------------+---------------+
| Paget\'s disease in nipple                                     | 4 (1.38)       | 2 (1.65)        | 3 (1.55)      |
+----------------------------------------------------------------+----------------+-----------------+---------------+

Abbreviations: DCIS, ductal carcinoma in situ; DCISM, ductal carcinoma in situ with microinvasion; IBC, invasive breast cancer.

Solid papillary carcinoma and encapsulated papillary carcinoma.

Invasive lobular carcinoma, invasive papillary carcinoma, invasive micropapillary carcinoma, invasive neuroendocrine carcinoma.

John Wiley & Sons, Ltd

The trends in surgical options have hardly altered over time, whereas the paradigm of axillary evaluation has changed (Figure [1](#cam42623-fig-0001){ref-type="fig"}A,B). SLNB was introduced at our institution in 2006 and was performed by only a few surgeons in the first few years. Before 2012, nearly one third of patients in average underwent ALND, however, the percentile significantly decreased to 2.60% in 2015 (Table [3](#cam42623-tbl-0003){ref-type="table"}). Because of the increase in the prevalence of SLNB, we divided the whole cohort according to time periods: 2006‐2012 and 2013‐2015. We further analyzed upstaging and axillary metastasis in these two periods. We found that the proportion of upstaging decreased from 60.68% to 46.49% (*P* = .002; Figure [2](#cam42623-fig-0002){ref-type="fig"}A), which might because of the increase in preoperatively MRI (*P* \< .001). While, the rate of axillary metastasis had no significant difference in these two periods (Figure [2](#cam42623-fig-0002){ref-type="fig"}B).

![Trends in surgical options (A) and axillary evaluation (B) of patients preoperatively diagnosed with pure ductal carcinoma in situ by core needle biopsy at FUSCC from 2006 to 2015](CAM4-8-7586-g001){#cam42623-fig-0001}

###### 

Trends in surgical options and axillary evaluation from 2006 to 2015 in FUSCC

  Year        Total   Mastectomy   \%      BCS   \%      SLNB   \%      ALND   \%
  ----------- ------- ------------ ------- ----- ------- ------ ------- ------ -------
  2006‐2008   21      19           90.48   2     9.52    4      19.05   17     80.95
  2009‐2010   62      57           91.94   5     8.06    40     64.52   22     35.48
  2011        69      66           95.65   3     4.35    50     72.46   19     27.54
  2012        82      77           93.90   5     6.10    71     86.59   11     13.41
  2013        95      85           89.47   10    10.53   86     90.53   9      9.47
  2014        121     110          90.91   11    9.09    112    92.56   9      7.44
  2015        154     134          87.01   20    12.99   150    97.40   4      2.60
  Total       604     548          90.73   56    9.27    513    84.93   91     15.07

Abbreviations: ALND, axillary lymph node dissection; BCS, breast‐conserving surgery; SLNB, sentinel lymph node biopsy.

John Wiley & Sons, Ltd

![Comparison of proportion of upstaging (A) and axillary metastasis (B) in patients preoperatively diagnosed with pure ductal carcinoma in situ by core needle biopsy between 2006--2012 and 2013--2015](CAM4-8-7586-g002){#cam42623-fig-0002}

3.2. Axillary lymph nodes status {#cam42623-sec-0012}
--------------------------------

Of all patients, 513 (84.93%) underwent SLNB and 91 (15.07%) underwent ALND. Positive ALNs were identified in 41 (6.79%) patients based on the final paraffin section pathology, of which 85.37% (35/41) had one to two positive ALNs, 14.63% (6/41) had three or more positive ALNs. Among the patients with positive ALNs, 30 patients received SLNB: four patients with isolated tumor cells, six patients with micrometastasis, and 20 patients with macrometastasis.

Of the 513 patients who received SLNB, 30 of them had positive SLNs. Of these 30 patients, 22 of them received further axillary evaluation, and three showed positive in ALND. All three patients were IBC patients. The rate of axillary node positivity after a positive sentinel node was 10.00% (3/30) (Table [4](#cam42623-tbl-0004){ref-type="table"}). We further found that the finding of positive ALNs was correlated with the extent of invasion at the final pathology. Positive ALNs occurred in 1.38% (4/290) of the patients with pure DCIS, 3.31% (4/121) of the patients with microinvasion, and 17.10% (33/193) of the patients with IBC (*P* \< .001). However, this correlation was not shown between patients with DCIS and DCISM in pairwise comparison (*P* = .198).

###### 

Correlation of the rate of positive SLNs and the rate of positive nodes after ALND for patients in different groups according to their final pathology

+-------+------------------------+---------------+-----------------------+---------------+
|       | Patients received SLNB | Positive SLNs | Further received ALND | Positive ALND |
|       |                        |               |                       |               |
|       | N = 513                | N = 30        | N = 22                | N = 3         |
+=======+========================+===============+=======================+===============+
| DCIS  | 261                    | 4             | 3                     | 0             |
+-------+------------------------+---------------+-----------------------+---------------+
| DCISM | 103                    | 4             | 2                     | 0             |
+-------+------------------------+---------------+-----------------------+---------------+
| IBC   | 149                    | 22            | 17                    | 3             |
+-------+------------------------+---------------+-----------------------+---------------+

John Wiley & Sons, Ltd

3.3. Predictors of upstaging on final pathology {#cam42623-sec-0013}
-----------------------------------------------

Various clinicopathological factors were examined in order to determine predictors of upstaging on final pathology (Table [5](#cam42623-tbl-0005){ref-type="table"}). Compared with patients in DCIS group, patients with upstaging tend to have larger tumor size on ultrasonography (61.15% vs 47.93%, *P* = .005) and higher Ki67 level (72.61% vs 65.52%, *P* = .046). Also, patients underwent mastectomy or patients with multifocal lesions had the trends of being upstaged, which did not reach significant differences. The two groups were comparable in age (*P* = .230), breast cancer family history (*P* = .229), body mass index (BMI) (*P* = .881), lesion classification (*P* = .169), and tumor position (*P* = .656), whereas they differed in the profile of molecular subtype (*P* = .007). Predictors with *P* \< .05 in the univariate analysis were included in a multivariate logistic regression analysis, which showed that patients with larger tumor size on ultrasonography (\>2.0 cm) (OR 1.786, 95% CI 1.237‐2.580, *P* = .002) were more likely to be upstaged on final pathology. Also, ER+HER2+ patients were more likely to be upstaged than ER+HER2− patients (OR 1.874, 95% CI 1.095‐3.206, *P* = .022).

###### 

Univariate and multivariate analysis of predictors of upstaging on final pathology

+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Variables                     | DCIS     | \%    | DCISM&IBC | \%    | Univariate | Multivariate                  |
|                               |          |       |           |       |            |                               |
|                               | N = 290  |       | N = 314   |       | *P*‐value  | OR (95% CI), *P*‐value        |
+===============================+==========+=======+===========+=======+============+===============================+
| Tumor size on ultrasonography | **.005** |       |           |       |            |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| cT1                           | 127      | 43.79 | 102       | 32.48 |            | Ref                           |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| cT2‐3                         | 139      | 47.93 | 192       | 61.15 |            | 1.786 (1.237‐2.580), **.002** |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Unknown                       | 24       | 8.28  | 20        | 6.37  |            |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Ki67                          |          |       |           |       | **.046**   |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| ≤14%                          | 78       | 26.90 | 58        | 18.47 |            | Ref                           |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| \>14%                         | 190      | 65.52 | 228       | 72.61 |            | 1.547 (0.989‐2.421), .056     |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Unknown                       | 22       | 7.59  | 28        | 8.92  |            |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Molecular type                |          |       |           |       | **.007**   |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| ER+HER2−                      | 116      | 40.00 | 111       | 35.35 |            | Ref                           |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| ER+HER+                       | 39       | 13.45 | 74        | 23.57 |            | 1.874 (1.095‐3.206), **.022** |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| ER−HER2+                      | 106      | 36.55 | 94        | 29.94 |            | 0.753 (0.479‐1.184), .220     |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| ER−HER2‐                      | 22       | 7.59  | 32        | 10.19 |            | 1.703 (0.877‐3.305), .116     |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+
| Unknown                       | 7        | 2.41  | 3         | 0.96  |            |                               |
+-------------------------------+----------+-------+-----------+-------+------------+-------------------------------+

Abbreviations: CI, confidence interval; DCIS, ductal carcinoma in situ; DCISM, ductal carcinoma in situ with microinvasion; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IBC, invasive breast cancer; OR, odd ratio.

Bold indicates significant *P*‐values (*P* \< .05).

John Wiley & Sons, Ltd

3.4. Factors associated with axillary lymph nodes metastasis {#cam42623-sec-0014}
------------------------------------------------------------

Univariate and multivariate analysis were performed in order to investigate factors associated with positive ALNs (Table [6](#cam42623-tbl-0006){ref-type="table"}). In univariate analysis, compared with patients in ALN− group, patients in ALN+ group were more likely to have larger tumor size on pathology (\>2 cm) (80.49% vs 64.48%, *P* = .037) and multifocal lesions (9.76% vs 3.37%, *P* = .039). Both factors reached statistical significance in multivariate analysis. Patients with larger tumor size on pathology (\>2 cm) and multifocal lesions had 2.336‐fold and 3.354‐fold greater risks of axillary metastasis, respectively (95% CI 1.047‐5.213, *P* = .038; 95% CI 1.065‐10.564, *P* = .039).

###### 

Univariate and multivariate analysis of factors associated with axillary lymph nodes status

+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| Variables               | ALN+   | \%    | ALN‐    | \%    | Univariate | Multivariate                   |
|                         |        |       |         |       |            |                                |
|                         | N = 41 |       | N = 563 |       | *P*‐value  | OR (95% CI), *P*‐value         |
+=========================+========+=======+=========+=======+============+================================+
| Tumor size on pathology |        |       |         |       | **.037**   |                                |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| ≤2 cm                   | 8      | 19.51 | 200     | 35.52 |            | Ref                            |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| \>2 cm                  | 33     | 80.49 | 363     | 64.48 |            | 2.336 (1.047‐5.213), **.038**  |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| Number of lesions       |        |       |         |       | **.039**   |                                |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| Unifocal                | 37     | 90.24 | 544     | 96.63 |            | Ref                            |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+
| Multifocal              | 4      | 9.76  | 19      | 3.37  |            | 3.354 (1.065‐10.564), **.039** |
+-------------------------+--------+-------+---------+-------+------------+--------------------------------+

Abbreviations: ALNs, axillary lymph nodes; CI, confidence interval; OR, odd ratio.

Bold indicates significant *P*‐values (*P* \< .05).

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42623-sec-0015}
=============

This study has investigated the factors associated with DCIS upstaging and axillary metastasis. The rate of upstaging to DCISM and IBC was 20.03% and 31.95%, respectively. Independent predictors of upstaging included larger tumor size on ultrasonography (\>2 cm) and molecular subtype (ER+HER2+). Axillary metastasis rate was 6.79%. Factors associated with positive ALNs were larger tumor size on pathology (\>2 cm) and multifocal lesions.

In previous studies, approximately 26% of patients diagnosed with DCIS was upstaged to IBC (range 8.8%‐51.5%).[3](#cam42623-bib-0003){ref-type="ref"}, [4](#cam42623-bib-0004){ref-type="ref"}, [5](#cam42623-bib-0005){ref-type="ref"}, [6](#cam42623-bib-0006){ref-type="ref"}, [7](#cam42623-bib-0007){ref-type="ref"}, [8](#cam42623-bib-0008){ref-type="ref"}, [9](#cam42623-bib-0009){ref-type="ref"}, [10](#cam42623-bib-0010){ref-type="ref"}, [11](#cam42623-bib-0011){ref-type="ref"} And the rate of upstaging to DCISM ranged 4%‐29.6%.[15](#cam42623-bib-0015){ref-type="ref"}, [16](#cam42623-bib-0016){ref-type="ref"}, [17](#cam42623-bib-0017){ref-type="ref"} In this study, we have reported a relatively high rate of underestimation, 51.98% in total without subgrouping either upstaging to microinvasion or IBC. This variable proportion of upstaging could be a result of pathologists' interpretation factors.[18](#cam42623-bib-0018){ref-type="ref"} Our current findings on independent predictors of upstaging are consistent with previous reports. A meta‐analysis reported by Brennan M E et al, which included 7350 cases of DCIS diagnosed by CNB, showed that tumor size was one of the strongest independent predictors of underestimation.[18](#cam42623-bib-0018){ref-type="ref"} In numerous previous studies, large tumor size, palpable lump, and number of lesions were associated with the risk of upstaging.[2](#cam42623-bib-0002){ref-type="ref"}, [8](#cam42623-bib-0008){ref-type="ref"}, [15](#cam42623-bib-0015){ref-type="ref"}, [18](#cam42623-bib-0018){ref-type="ref"}, [19](#cam42623-bib-0019){ref-type="ref"}, [20](#cam42623-bib-0020){ref-type="ref"}, [21](#cam42623-bib-0021){ref-type="ref"} Other factors, such as nuclear grade, comedo necrosis, sclerosing adenosis, and CNB method, were also correlated with upstaging.[2](#cam42623-bib-0002){ref-type="ref"}, [8](#cam42623-bib-0008){ref-type="ref"}, [18](#cam42623-bib-0018){ref-type="ref"}, [19](#cam42623-bib-0019){ref-type="ref"}, [20](#cam42623-bib-0020){ref-type="ref"} Studies on molecular subtype as a predictor of upstaging are rare.[8](#cam42623-bib-0008){ref-type="ref"}, [19](#cam42623-bib-0019){ref-type="ref"}, [21](#cam42623-bib-0021){ref-type="ref"}, [22](#cam42623-bib-0022){ref-type="ref"} Some studies showed a correlation between negative hormone receptor (HR) and invasion of DCIS,[8](#cam42623-bib-0008){ref-type="ref"}, [21](#cam42623-bib-0021){ref-type="ref"} and others showed that positive HER2 status was associated with upstaging.[19](#cam42623-bib-0019){ref-type="ref"}, [22](#cam42623-bib-0022){ref-type="ref"} In this study, we have identified several independent predictors of underestimation, and larger tumor size on ultrasonography (\>2 cm) was the strongest.

In our study, the rate of positive ALNs was 6.79%, which was comparable with a previous meta‐analysis reported by Ansari B et al, showing that the axillary metastasis rate was 7.4% in patients with DCIS diagnosed by CNB.[23](#cam42623-bib-0023){ref-type="ref"} Also, we identified larger tumor size and multifocal lesions as factors associated with axillary metastasis. Theoretically, DCIS is defined on the basis that the cancer has not broken through the basement membrane of the breast duct, which means it does not have the potential to metastasize, thus, no axillary evaluation is needed. While, with the major issue of upstaging in preoperative DCIS diagnosis, whether these patients need axillary evaluation is controversial due to the risk of axillary metastasis. Previous data showed, the overall axillary metastasis rate was 5% in DCIS patients, which was most likely due to underlying invasive carcinoma, however, it increased to 10%‐20% if preoperatively underestimated was proved on final pathology.[2](#cam42623-bib-0002){ref-type="ref"}, [10](#cam42623-bib-0010){ref-type="ref"}, [24](#cam42623-bib-0024){ref-type="ref"}, [25](#cam42623-bib-0025){ref-type="ref"}, [26](#cam42623-bib-0026){ref-type="ref"} In this study, 1.38% and 3.31% of patients had positive ALNs in DCIS and DCISM group, separately, which showed no significant difference. However, 17.10% of patients with IBC showed axillary metastasis. Thus, when performing axillary evaluation at the primary operation, surgeons are faced with the dilemma of avoiding second operation if the final pathology upstaged, or performing an unnecessary procedure in pure DCIS patients.

Routine axillary evaluation in all patients diagnosed with DCIS preoperatively is not justified, due to the low rate of axillary metastasis and complications after axillary evaluation. Even though SLNB had lower rate of complications than ALND, its morbidity is not insignificant, with 41% of patients having upper extremity impairment at 7 years.[27](#cam42623-bib-0027){ref-type="ref"}, [28](#cam42623-bib-0028){ref-type="ref"} In this study, despite of a 51.98% upstaging rate, the rate of axillary metastasis is relatively low, which may support the omission of axillary evaluation in selected patients.

For DCIS patients, NCCN guideline recommended that axillary evaluation could be omitted in patients with BCS, whereas patients with mastectomy could receive SLNB considering primary operation may result in losing opportunity of future SLNB.[13](#cam42623-bib-0013){ref-type="ref"} For DCISM patients, axillary evaluation was still under debate. According to our study, patients with DCIS and DCISM on final pathology had similar metastasis rate, showing that the clinical meaning of upstaging from DCIS to DCISM is relatively limited. For IBC patients with clinically negative axillary, both NCCN and ASCO guidelines recommended SLNB.[12](#cam42623-bib-0012){ref-type="ref"}, [13](#cam42623-bib-0013){ref-type="ref"} However, in this study, 82.9% (160/193) of patients in IBC group had negative ALNs, 16.06% (31/193) had one to three positive ALNs, and only two patients had more than three positive ALNs. Interestingly, these two patients had the same histological type, both were invasive micropapillary carcinoma, which were proved to have worse prognosis than most histological types. Thus, axillary evaluation may also be omitted in IBC patients with low risk of axillary metastasis.

Certain measures should be taken place to reduce the upstage rate. First, we need to choose biopsy method carefully for these patients, in particularly some patients with calcification may be more suitable for vacuum‐assisted biopsy. Second, we should provide more choices in CNB, such as 8‐gauge CNB. The accuracy of preoperative diagnosis is in accordance with the quantity of samples. Third, the quantity of biopsy samples can be more individualized. According to this study, patients with larger tumor size on ultrasonography (\>2.0 cm) are more likely to be upstaged on final pathology. Thus, biopsy samples should be taken more to improve the accuracy of their preoperative diagnosis.

According to our study, predictors of upstaging and axillary metastasis were not completely consistent, thus, the selective axillary evaluation for patients with a higher risk of upstaging may not accurately identify those with positive ALNs. After integrating predictors of upstaging and factors associated with positive ALNs in this study, we found that patients with larger tumor size (\>2 cm), multifocal lesions or ER+HER2+ status were more likely to be upstaging patients with positive ALNs, who might need axillary evaluation more than patients with relatively low risk of upstaging or axillary metastasis. In previous studies, some authors also suggested that SLNB could be performed only for cases with high‐risk features, because the clinical benefit of SLNB needed to be balanced against the risk of complications.[29](#cam42623-bib-0029){ref-type="ref"}, [30](#cam42623-bib-0030){ref-type="ref"} In the future, we may able to further identify patients who can avoid unnecessary axillary evaluation based on their clinicopathological predictors, in conjunction with continued progress in adjuvant radiotherapy and systematic therapy which may be adequate to control axillary status in clinically negative patients.

There are some limitations to this study. First, this was a retrospective study. However, this was a relatively large dataset with uniform inclusive and exclusive criteria. Second, not all histological grades on CNB pathology were reported in our institution. While, according to previous studies, we believe that histological grade may be an important predictor of upstaging or axillary metastasis.[2](#cam42623-bib-0002){ref-type="ref"}, [8](#cam42623-bib-0008){ref-type="ref"}, [27](#cam42623-bib-0027){ref-type="ref"} Finally, the sample volume for preoperative pathological diagnosis were unknown. It is obvious that the accuracy of preoperative diagnosis is in accordance with the number of samples. Further assessment is needed to select patients with low risk of axillary metastasis, who can safely omit axillary evaluation.

5. CONCLUSION {#cam42623-sec-0016}
=============

Overall, our study demonstrated that, for patients diagnosed with DCIS by CNB, larger tumor size on ultrasonography (\>2 cm) and molecular subtype (ER+HER2+) were two independent predictors of upstaging, whereas larger tumor size on pathology (\>2 cm) and multifocal lesions were the strongest risk factors of axillary metastasis. Axillary evaluation was recommended in patients with larger tumor size (\>2 cm), multifocal lesions or ER+HER2+ status. Despite of a 51.98% upstaging rate, the rate of axillary metastasis in these patients is relatively low, suggesting that axillary evaluation can be omitted in selected patients who have a low risk of upstaging or axillary metastasis.
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